https://ir.skyebioscience.com/ https://ir.skyebioscience.com/news-releases https://ir.skyebioscience.com/company-information/highlights https://ir.skyebioscience.com/company-information/corporate-presentation https://ir.skyebioscience.com/company-information/ir-calendar-webcasts https://ir.skyebioscience.com/company-information/email-alerts https://ir.skyebioscience.com/company-information/contacts https://ir.skyebioscience.com/company-information/faq https://ir.skyebioscience.com/financial-information https://ir.skyebioscience.com/financial-information/financial-results https://ir.skyebioscience.com/financial-information/income-statement https://ir.skyebioscience.com/financial-information/balance-sheet https://ir.skyebioscience.com/financial-information/cash-flow https://ir.skyebioscience.com/stock-data/analyst-coverage https://ir.skyebioscience.com/stock-data/quote-chart https://ir.skyebioscience.com/stock-data/historical-data https://ir.skyebioscience.com/sec-filings/all-sec-filings https://ir.skyebioscience.com/sec-filings/annual-reports https://ir.skyebioscience.com/sec-filings/quarterly-reports https://ir.skyebioscience.com/sec-filings/section-16-filings https://ir.skyebioscience.com/corporate-governance https://ir.skyebioscience.com/corporate-governance/board-committees https://ir.skyebioscience.com/news-releases/detail/256/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development 2026-04-02T07:00:05-04:00 https://ir.skyebioscience.com/news-releases/detail/255/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update 2026-03-10T16:01:02-04:00 https://ir.skyebioscience.com/news-releases/detail/254/skye-bioscience-to-announce-2025-financial-results-and-business-update-on-march-10-2026 2026-03-05T07:00:01-05:00 https://ir.skyebioscience.com/news-releases/detail/253/skye-reports-positive-cbeyond-phase-2a-extension-interim-study-results-for-nimacimab-in-combination-with-semaglutide 2026-02-02T07:00:09-05:00 https://ir.skyebioscience.com/news-releases/detail/252/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference 2026-01-29T07:00:09-05:00 https://ir.skyebioscience.com/news-releases/detail/251/skye-bioscience-to-present-poster-at-keystone-obesity-conference 2026-01-21T07:00:01-05:00 https://ir.skyebioscience.com/news-releases/detail/250/skye-provides-2026-corporate-outlook 2026-01-12T07:00:06-05:00 https://ir.skyebioscience.com/news-releases/detail/249/halozyme-and-skye-bioscience-announce-global-collaboration-and-license-agreement-to-evaluate-nimacimab-co-formulated-with-enhanze-for-obesity 2026-01-05T07:00:08-05:00 https://ir.skyebioscience.com/news-releases/detail/248/skye-bioscience-to-participate-in-upcoming-investment-conferences 2025-11-24T07:00:51-05:00 https://ir.skyebioscience.com/news-releases/detail/247/skye-bioscience-reports-third-quarter-2025-financial-results-and-business-update 2025-11-10T16:01:06-05:00 https://ir.skyebioscience.com/news-releases/detail/246/skye-bioscience-late-breaking-oral-abstract-at-obesityweek-2025-to-highlight-improvement-in-rebound-weight-gain 2025-11-05T07:05:03-05:00 https://ir.skyebioscience.com/news-releases/detail/245/skye-bioscience-to-announce-third-quarter-2025-financial-results-and-business-update-on-november-10-2025 2025-11-05T07:00:22-05:00 https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial 2025-10-06T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/243/skye-presents-phase-1b-data-for-its-peripheral-cb1-inhibiting-antibody-nimacimab-at-european-association-for-the-study-of-diabetes-easd-annual-meeting 2025-09-19T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/242/skyes-cb1-inhibitor-nimacimab-demonstrates-superior-weight-loss-and-differentiated-mechanisms-from-monlunabant-and-continues-to-show-enhanced-combination-with-tirzepatide-with-durable-post-treatment-weight-maintenance-in-dio-model 2025-09-04T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/241/skye-completes-26-week-treatment-phase-in-phase-2a-cbeyondstudy 2025-09-02T07:00:11-04:00 https://ir.skyebioscience.com/news-releases/detail/240/skye-bioscience-to-host-virtual-kol-event-and-provide-perspectives-on-upcoming-cbeyond-phase-2a-topline-clinical-data-readout 2025-08-27T07:00:07-04:00 https://ir.skyebioscience.com/news-releases/detail/239/skye-bioscience-to-participate-in-upcoming-investment-and-medical-conferences 2025-08-21T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/238/skye-bioscience-reports-second-quarter-2025-financial-results-and-business-update 2025-08-07T16:01:08-04:00 https://ir.skyebioscience.com/news-releases/detail/237/skye-bioscience-to-announce-second-quarter-2025-financial-results-and-business-update-on-august-7-2025 2025-07-30T07:00:07-04:00 https://ir.skyebioscience.com/news-releases/detail/236/skye-bioscience-shares-nimacimab-anatomy-of-progress-video-series-and-highlights-preclinical-cb1-antibody-data-presented-at-the-american-diabetes-associations-85th-scientific-sessions 2025-06-23T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/235/skye-bioscience-to-present-expanded-preclinical-cb1-antibody-data-at-the-american-diabetes-associations-85th-scientific-sessions 2025-06-17T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/234/skye-bioscience-to-participate-in-upcoming-investment-conferences 2025-05-22T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/233/skye-bioscience-establishes-partnership-with-arecor-therapeutics-to-develop-enhanced-formulation-of-obesity-candidate-nimacimab 2025-05-19T05:00:50-04:00 https://ir.skyebioscience.com/news-releases/detail/232/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-05-13T16:05:02-04:00 https://ir.skyebioscience.com/news-releases/detail/231/skye-bioscience-clinical-model-demonstrating-necessity-of-peripheral-cb1-inhibition-for-weight-loss-presented-at-european-congress-on-obesity 2025-05-13T07:00:08-04:00 https://ir.skyebioscience.com/news-releases/detail/230/skye-bioscience-reports-first-quarter-2025-results-and-highlights-nimacimab-differentiation-in-obesity 2025-05-08T16:01:01-04:00 https://ir.skyebioscience.com/news-releases/detail/229/skye-bioscience-to-announce-2025-first-quarter-financial-results-on-may-8th-2025 2025-05-07T07:00:10-04:00 https://ir.skyebioscience.com/news-releases/detail/228/skye-bioscience-to-participate-in-may-investment-and-medical-conferences 2025-04-29T07:00:05-04:00 https://ir.skyebioscience.com/news-releases/detail/227/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-04-25T20:06:26-04:00 https://ir.skyebioscience.com/news-releases/detail/226/skye-bioscience-demonstrates-over-30-weight-loss-with-nimacimab-and-tirzepatide-combination-in-preclinical-model 2025-04-15T07:00:08-04:00 https://ir.skyebioscience.com/news-releases/detail/225/skye-bioscience-to-conduct-meetings-at-piper-sandler-conference 2025-04-14T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/224/skye-bioscience-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update 2025-03-20T16:01:14-04:00 https://ir.skyebioscience.com/news-releases/detail/223/skye-bioscience-to-announce-2024-financial-results-on-march-20th-2025 2025-03-14T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/222/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-02-27T18:00:59-05:00 https://ir.skyebioscience.com/news-releases/detail/221/skye-bioscience-to-participate-in-sxsw-session-on-obesity 2025-02-24T10:51:56-05:00 https://ir.skyebioscience.com/news-releases/detail/220/skye-bioscience-to-present-at-td-cowen-health-care-conference 2025-02-20T07:00:12-05:00 https://ir.skyebioscience.com/news-releases/detail/219/skye-bioscience-announces-participation-in-february-conferences 2025-02-04T07:00:06-05:00 https://ir.skyebioscience.com/news-releases/detail/218/skye-bioscience-provides-2025-look-ahead-and-year-in-review 2025-01-13T07:00:25-05:00 https://ir.skyebioscience.com/news-releases/detail/217/skye-bioscience-to-present-at-j-p-morgan-healthcare-conference 2024-12-19T07:00:49-05:00 https://ir.skyebioscience.com/news-releases/detail/216/skye-bioscience-to-participate-in-upcoming-december-healthcare-investment-conferences 2024-11-18T07:00:25-05:00 https://ir.skyebioscience.com/news-releases/detail/215/skye-bioscience-surpasses-50-patient-enrollment-in-phase-2-obesity-study-of-differentiated-cb1-inhibitor 2024-11-14T07:00:15-05:00 https://ir.skyebioscience.com/news-releases/detail/214/skye-bioscience-reports-third-quarter-2024-financial-results-and-recent-highlights 2024-11-07T16:01:13-05:00 https://ir.skyebioscience.com/news-releases/detail/213/skye-bioscience-demonstrates-prominent-role-of-peripheral-cb1-inhibition-and-achieves-significant-weight-loss-with-novel-cb1-inhibiting-antibody-nimacimab-in-preclinical-model 2024-11-04T07:00:04-05:00 https://ir.skyebioscience.com/news-releases/detail/212/skye-bioscience-to-announce-third-quarter-2024-results 2024-11-01T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/211/skye-bioscience-names-independent-director-paul-grayson-as-chairman-of-the-board 2024-10-29T07:00:13-04:00 https://ir.skyebioscience.com/news-releases/detail/210/skye-bioscience-to-participate-in-upcoming-november-healthcare-investment-conferences 2024-10-21T07:00:01-04:00 https://ir.skyebioscience.com/news-releases/detail/209/skye-bioscience-comments-on-monlunabant-phase-2-top-line-data-and-reiterates-confidence-in-nimacimab-clinical-development-plan 2024-09-23T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/208/skye-bioscience-appoints-puneet-s-arora-md-as-chief-medical-officer 2024-09-03T07:00:06-04:00 https://ir.skyebioscience.com/news-releases/detail/207/skye-bioscience-to-participate-in-upcoming-healthcare-investment-conferences 2024-08-26T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/206/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-08-23T18:45:37-04:00 https://ir.skyebioscience.com/news-releases/detail/205/skye-bioscience-launches-phase-2-cbeyond-clinical-trial-of-its-differentiated-cb1-inhibitor-nimacimab-in-patients-with-obesity 2024-08-22T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/204/skye-bioscience-reports-second-quarter-2024-financial-results-and-recent-highlights 2024-08-09T17:59:38-04:00 https://ir.skyebioscience.com/news-releases/detail/203/skye-bioscience-hosts-virtual-kol-event-metabolic-rewiring-with-cb1-inhibition-and-details-phase-2-nimacimab-clinical-trial-design-including-obstructive-sleep-apnea-exploratory-endpoints 2024-07-24T06:00:01-04:00 https://ir.skyebioscience.com/news-releases/detail/202/skye-bioscience-to-host-virtual-kol-event-metabolic-rewiring-with-cb1-inhibition-on-july-24th 2024-07-11T07:15:01-04:00 https://ir.skyebioscience.com/news-releases/detail/200/skye-bioscience-appoints-dr-karen-smith-to-board-of-directors 2024-07-03T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/199/skye-bioscience-added-to-russell-2000-and-russell-3000-indexes 2024-07-01T07:00:13-04:00 https://ir.skyebioscience.com/news-releases/detail/198/skye-bioscience-participating-in-piper-sandler-virtual-obesity-day 2024-06-25T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/197/skye-concentrates-strategy-and-clinical-development-focus-on-nimacimab-metabolic-program 2024-06-10T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/196/skye-bioscience-to-present-at-jefferies-global-healthcare-conference 2024-06-03T07:00:09-04:00 https://ir.skyebioscience.com/news-releases/detail/195/skye-bioscience-highlights-novel-synthetic-cannabinoid-based-library-capable-of-modulating-the-endocannabinoid-system-to-treat-ocular-diseases-at-arvo-2024-annual-meeting 2024-05-10T07:00:05-04:00 https://ir.skyebioscience.com/news-releases/detail/194/skye-bioscience-to-present-two-posters-at-association-for-research-in-vision-and-ophthalmology-arvo-2024-annual-meeting 2024-04-30T07:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/193/skye-bioscience-to-present-at-upcoming-investment-conferences 2024-04-23T07:00:01-04:00 https://ir.skyebioscience.com/news-releases/detail/192/skye-bioscience-uplists-to-the-nasdaq-global-market 2024-04-10T08:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/191/skye-bioscience-announces-40-million-private-placement-equity-financing 2024-03-11T09:21:02-04:00 https://ir.skyebioscience.com/news-releases/detail/190/skye-bioscience-appoints-dr-annalisa-jenkins-to-board-of-directors 2024-03-04T07:00:03-05:00 https://ir.skyebioscience.com/news-releases/detail/189/skye-bioscience-completes-enrollment-of-phase-2a-clinical-trial-of-sbi-100-ophthalmic-emulsion-in-glaucoma-and-ocular-hypertension 2024-02-26T07:00:17-05:00 https://ir.skyebioscience.com/news-releases/detail/188/skye-bioscience-to-present-at-oppenheimer-investor-conference 2024-02-07T07:00:41-05:00 https://ir.skyebioscience.com/news-releases/detail/187/skye-bioscience-announces-50-25-million-private-placement-equity-financing 2024-01-29T08:00:36-05:00 https://ir.skyebioscience.com/news-releases/detail/186/skye-bioscience-receives-ind-clearance-for-phase-2-clinical-trial-of-nimacimab-in-obesity-and-chronic-kidney-disease 2024-01-09T07:00:35-05:00 https://ir.skyebioscience.com/news-releases/detail/185/skye-announces-clinical-development-plan-in-obesity-for-differentiated-peripheral-cb1-inhibitor-nimacimab 2023-12-11T07:00:03-05:00 https://ir.skyebioscience.com/news-releases/detail/184/skye-bioscience-responds-to-otc-markets-promotional-policy 2023-12-08T17:14:40-05:00 https://ir.skyebioscience.com/news-releases/detail/183/skye-bioscience-and-tautomer-bioscience-enter-exclusive-license-for-sbi-100-for-development-and-sale-of-products-for-chronic-pain-and-other-indications-in-south-africa-and-rest-of-africa 2023-12-05T07:00:35-05:00 https://ir.skyebioscience.com/news-releases/detail/182/skye-bioscience-treats-first-patient-in-glaucoma-phase-2-study-of-sbi-100-ophthalmic-emulsion 2023-11-28T07:00:02-05:00 https://ir.skyebioscience.com/news-releases/detail/181/skye-bioscience-to-present-at-btig-ophthalmology-day-and-ois-xiii-ophthalmology-innovation-summit 2023-11-21T07:00:31-05:00 https://ir.skyebioscience.com/news-releases/detail/180/skye-bioscience-announces-positive-phase-1-trial-results-for-sbi-100-ophthalmic-emulsion-its-first-in-class-cb1-agonist-being-developed-for-the-treatment-of-glaucoma 2023-10-25T07:00:39-04:00 https://ir.skyebioscience.com/news-releases/detail/179/correction-skye-bioscience-to-host-virtual-investor-day-on-october-25-2023-cb1-axis-unlocking-the-pharmaceutical-potential-of-the-endocannabinoid-system 2023-10-20T00:59:51-04:00 https://ir.skyebioscience.com/news-releases/detail/178/skye-bioscience-to-host-virtual-investor-day-on-october-25-2023-cb1-axis-unlocking-the-pharmaceutical-potential-of-the-endocannabinoid-system 2023-10-19T18:56:10-04:00 https://ir.skyebioscience.com/news-releases/detail/177/skye-bioscience-receives-clinical-site-approvals-for-glaucoma-phase-2a-trial 2023-09-27T07:00:30-04:00 https://ir.skyebioscience.com/news-releases/detail/176/skye-bioscience-announces-participation-at-upcoming-investor-conferences 2023-09-22T07:15:42-04:00 https://ir.skyebioscience.com/news-releases/detail/175/skye-bioscience-reverse-stock-split-to-be-effective-on-september-8th 2023-09-07T13:00:38-04:00 https://ir.skyebioscience.com/news-releases/detail/174/skye-bioscience-to-present-at-h-c-wainwright-25th-annual-global-investment-conference 2023-09-05T13:12:17-04:00 https://ir.skyebioscience.com/news-releases/detail/173/skye-completes-17m-financing-and-acquires-novel-phase-2-ready-cb1-inhibiting-monoclonal-antibody 2023-08-21T07:00:20-04:00 https://ir.skyebioscience.com/news-releases/detail/172/skye-bioscience-to-present-at-h-c-wainwright-3rd-annual-ophthalmology-virtual-conference 2023-08-14T07:00:30-04:00 https://ir.skyebioscience.com/news-releases/detail/171/skye-bioscience-receives-positive-safety-review-for-final-cohort-of-fully-enrolled-phase-1-study-of-sbi-100-ophthalmic-emulsion 2023-07-13T07:00:23-04:00 https://ir.skyebioscience.com/news-releases/detail/170/skye-bioscience-completes-production-and-filling-of-investigational-drug-material-in-preparation-for-phase-2a-glaucoma-clinical-trial 2023-07-06T07:00:24-04:00 https://ir.skyebioscience.com/news-releases/detail/169/skye-bioscience-completes-enrollment-of-phase-1-clinical-trial-of-novel-cb1r-agonist-sbi-100-ophthalmic-emulsion 2023-06-12T07:00:24-04:00 https://ir.skyebioscience.com/news-releases/detail/168/skye-bioscience-to-present-at-ld-micro-invitational-xiii 2023-06-05T07:00:24-04:00 https://ir.skyebioscience.com/news-releases/detail/167/skye-bioscience-receives-positive-safety-review-of-fifth-cohort-of-phase-1-study-of-sbi-100-ophthalmic-emulsion 2023-06-02T07:00:23-04:00 https://ir.skyebioscience.com/news-releases/detail/166/skye-bioscience-begins-dosing-fifth-of-six-cohorts-in-phase-1-clinical-trial-of-novel-cb1r-agonist 2023-05-17T07:00:27-04:00 https://ir.skyebioscience.com/news-releases/detail/165/skye-bioscience-receives-positive-safety-review-in-first-multiple-administration-cohort-of-phase-1-study-of-sbi-100-ophthalmic-emulsion 2023-05-15T07:00:27-04:00 https://ir.skyebioscience.com/news-releases/detail/164/skye-bioscience-begins-dosing-phase-1-fourth-cohort-in-clinical-trial-of-novel-cb1r-agonist 2023-04-27T07:00:25-04:00 https://ir.skyebioscience.com/news-releases/detail/163/skye-bioscience-receives-positive-safety-review-of-third-cohort-in-phase-1-study-of-sbi-100-ophthalmic-emulsion 2023-04-04T07:00:24-04:00 https://ir.skyebioscience.com/news-releases/detail/162/skye-biosciences-novel-cannabinoid-derivative-reduces-pain-in-animal-model-results-published-in-scientific-journal 2023-04-03T07:00:41-04:00 https://ir.skyebioscience.com/news-releases/detail/160/skye-bioscience-receives-human-research-ethics-committee-approval-to-start-multiple-ascending-dose-arm-of-phase-1-study-of-sbi-100-ophthalmic-emulsion 2023-03-15T07:00:21-04:00 https://ir.skyebioscience.com/news-releases/detail/159/skye-bioscience-doses-third-cohort-of-phase-1-clinical-trial-of-sbi-100-ophthalmic-emulsion 2023-03-07T07:01:59-05:00 https://ir.skyebioscience.com/news-releases/detail/158/skye-bioscience-receives-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-second-cohort-of-phase-1-study 2023-02-23T07:00:20-05:00 https://ir.skyebioscience.com/news-releases/detail/157/skye-bioscience-appoints-deborah-charych-phd-to-board-of-directors 2023-02-16T07:00:25-05:00 https://ir.skyebioscience.com/news-releases/detail/156/skye-bioscience-closes-sale-of-subsidiary-verdlite-sciences-to-c3-souvenir-holding-with-usd5-60m-closing-payment 2023-02-15T07:00:21-05:00 https://ir.skyebioscience.com/news-releases/detail/155/skye-bioscience-doses-second-cohort-of-phase-1-clinical-trial-of-sbi-100-ophthalmic-emulsion 2023-02-13T07:00:35-05:00 https://ir.skyebioscience.com/news-releases/detail/154/skye-bioscience-retains-lexitas-pharma-services-as-cro-for-phase-2-trial-of-sbi-100-ophthalmic-emulsion 2023-02-02T07:00:25-05:00 https://ir.skyebioscience.com/news-releases/detail/153/skye-bioscience-achieves-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-phase-1-first-cohort 2023-01-31T07:00:27-05:00 https://ir.skyebioscience.com/news-releases/detail/152/skye-bioscience-obtains-central-irb-approval-for-phase-2-clinical-trial-with-sbi-100-ophthalmic-emulsion 2023-01-27T07:00:22-05:00 https://ir.skyebioscience.com/news-releases/detail/151/skye-bioscience-receives-fda-authorization-of-investigational-new-drug-application-for-sbi-100-oe 2022-12-20T07:00:22-05:00 https://ir.skyebioscience.com/news-releases/detail/150/skye-bioscience-doses-first-cohort-of-participants-in-phase-1-clinical-trial-of-sbi-100-ophthalmic-emulsion 2022-12-16T07:00:20-05:00 https://ir.skyebioscience.com/news-releases/detail/149/skye-bioscience-appoints-chris-twitty-phd-as-chief-scientific-officer 2022-12-13T07:00:24-05:00 https://ir.skyebioscience.com/news-releases/detail/148/skye-bioscience-to-present-at-rhk-2022-disruptive-growth-conference 2022-11-22T07:00:21-05:00 https://ir.skyebioscience.com/news-releases/detail/147/skye-bioscience-submits-investigational-new-drug-application-for-sbi-100-ophthalmic-emulsion-to-fda 2022-11-17T07:00:21-05:00 https://ir.skyebioscience.com/news-releases/detail/146/skye-bioscience-initiates-first-in-human-phase-1-clinical-trial-for-sbi-100 2022-11-16T07:00:25-05:00 https://ir.skyebioscience.com/news-releases/detail/145/skye-bioscience-closes-acquisition-of-emerald-health-therapeutics 2022-11-11T00:17:36-05:00 https://ir.skyebioscience.com/news-releases/detail/144/emerald-health-therapeutics-and-skye-bioscience-announce-intended-closing-date-of-plan-of-arrangement 2022-11-07T23:25:41-05:00 https://ir.skyebioscience.com/news-releases/detail/143/skye-bioscience-stockholders-vote-in-favor-of-arrangement-agreement-with-emerald-health-therapeutics-inc 2022-09-30T15:24:08-04:00 https://ir.skyebioscience.com/news-releases/detail/142/skye-bioscience-completes-drug-production-for-phase-1-clinical-study 2022-09-20T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/141/skye-bioscience-files-definitive-proxy-statement-and-announces-stockholder-meeting-date 2022-09-01T07:00:17-04:00 https://ir.skyebioscience.com/news-releases/detail/140/skye-bioscience-reports-that-emerald-health-therapeutics-shareholders-voted-in-favor-of-plan-of-arrangement-with-skye 2022-08-19T15:22:20-04:00 https://ir.skyebioscience.com/news-releases/detail/139/skye-bioscience-selects-nextpharma-as-phase-2-contract-drug-manufacturer 2022-07-21T07:00:03-04:00 https://ir.skyebioscience.com/news-releases/detail/138/skye-bioscience-updates-phase-1-timeline 2022-07-20T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/137/skye-bioscience-receives-australian-ethics-committee-approval-to-start-first-in-human-phase-1-study-of-sbi-100-ophthalmic-emulsion 2022-06-30T07:00:26-04:00 https://ir.skyebioscience.com/news-releases/detail/136/skye-bioscience-expands-cannabinoid-pharmaceutical-innovation-program-with-leading-cannabinoid-medicinal-chemistry-groups 2022-06-07T07:00:04-04:00 https://ir.skyebioscience.com/news-releases/detail/135/skye-bioscience-to-present-at-ld-micro-invitational 2022-06-07T15:33:12-04:00 https://ir.skyebioscience.com/news-releases/detail/134/skye-bioscience-signs-arrangement-agreement-with-emerald-health-therapeutics 2022-05-12T09:05:10-04:00 https://ir.skyebioscience.com/news-releases/detail/133/skye-bioscience-reports-enhanced-intraocular-pressure-lowering-of-sbi-100-formulation-published-in-peer-reviewed-journal 2022-05-05T07:02:06-04:00 https://ir.skyebioscience.com/news-releases/detail/132/skye-bioscience-engages-clinical-trial-site-for-phase-1-study-in-agreement-with-cmax-clinical-research 2022-04-28T07:00:10-04:00 https://ir.skyebioscience.com/news-releases/detail/131/skye-bioscience-retains-novotech-as-cro-for-phase-1-trial-of-glaucoma-drug-candidate 2022-03-03T08:30:05-05:00 https://ir.skyebioscience.com/news-releases/detail/130/skye-bioscience-reports-positive-results-for-sbi-100-in-glp-toxicology-study 2022-02-16T08:30:06-05:00 https://ir.skyebioscience.com/news-releases/detail/129/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model 2022-02-01T08:30:03-05:00 https://ir.skyebioscience.com/news-releases/detail/128/skye-bioscience-issues-shareholder-letter-providing-progress-update-and-business-outlook-for-2022 2022-01-10T07:00:08-05:00 https://ir.skyebioscience.com/news-releases/detail/127/skye-bioscience-to-present-at-h-c-wainwright-bioconnect-virtual-conference 2022-01-04T08:30:01-05:00 https://ir.skyebioscience.com/news-releases/detail/126/skye-bioscience-expands-board-of-directors-with-the-appointment-of-life-sciences-executive-keith-w-ward-phd 2021-12-15T08:30:06-05:00 https://ir.skyebioscience.com/news-releases/detail/125/skye-bioscience-sponsored-research-presented-at-american-association-of-pharmaceutical-scientists-meeting-pharmsci-360 2021-10-21T08:30:04-04:00 https://ir.skyebioscience.com/news-releases/detail/124/skye-bioscience-establishes-new-cannabinoid-pharmaceutical-innovation-program 2021-10-12T13:35:02-04:00 https://ir.skyebioscience.com/news-releases/detail/123/skye-bioscience-appoints-head-of-regulatory-affairs-quality-assurance-and-senior-director-of-research-development 2021-10-07T09:00:08-04:00 https://ir.skyebioscience.com/news-releases/detail/122/skye-bioscience-appoints-kaitlyn-arsenault-as-chief-financial-officer 2021-10-05T08:30:02-04:00 https://ir.skyebioscience.com/news-releases/detail/121/skye-bioscience-announces-closing-of-7-0-million-registered-direct-offering 2021-09-29T16:30:02-04:00 https://ir.skyebioscience.com/news-releases/detail/120/skye-bioscience-announces-7-0-million-registered-direct-offering 2021-09-27T09:30:03-04:00 https://ir.skyebioscience.com/news-releases/detail/119/skye-bioscience-announces-thcvhs-late-breaking-preclinical-abstracts-selected-by-american-association-of-pharmaceutical-scientists-meeting-pharmsci-360 2021-09-21T09:00:02-04:00 https://ir.skyebioscience.com/news-releases/detail/118/skye-bioscience-announces-special-virtual-investor-presentation 2021-09-14T08:59:45-04:00 https://ir.skyebioscience.com/news-releases/detail/117/skye-bioscience-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference 2021-09-07T08:30:04-04:00 https://ir.skyebioscience.com/news-releases/detail/116/skye-bioscience-to-present-at-the-h-c-wainwright-ophthalmology-conference 2021-08-11T08:30:06-04:00 https://ir.skyebioscience.com/news-releases/detail/115/skye-bioscience-completes-thcvhs-ind-enabling-in-vitro-genotoxicity-studies 2021-08-10T08:30:05-04:00 https://ir.skyebioscience.com/news-releases/detail/114/skye-bioscience-appoints-biotech-executive-praveen-tyle-ph-d-to-board-of-directors 2021-07-26T08:30:01-04:00 https://ir.skyebioscience.com/news-releases/detail/113/skye-bioscience-expands-clinical-advisory-board-with-the-appointment-of-ophthalmology-expert-dr-miguel-gonzlez-andrades 2021-06-10T08:30:10-04:00 https://ir.skyebioscience.com/news-releases/detail/112/skye-biosciences-thcvhs-demonstrates-superior-therapeutic-benefit-compared-to-glaucoma-standard-of-care-both-as-combination-and-single-agent-in-preclinical-study 2021-05-17T08:42:44-04:00 https://ir.skyebioscience.com/news-releases/detail/111/skye-bioscience-completes-cmc-and-glp-production-for-thcvhs-lead-program 2021-04-22T08:30:05-04:00 https://ir.skyebioscience.com/news-releases/detail/110/skye-bioscience-to-present-at-upcoming-investment-conferences-in-april 2021-04-15T08:45:00-04:00 https://ir.skyebioscience.com/news-releases/detail/109/skye-bioscience-to-present-at-benzinga-biotech-small-cap-conference 2021-03-18T08:45:00-04:00 https://ir.skyebioscience.com/news-releases/detail/108/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment 2021-03-16T08:30:04-04:00 https://ir.skyebioscience.com/news-releases/detail/107/skye-bioscience-appoints-cannabinoid-science-experts-giovanni-appendino-phd-and-eduardo-muoz-md-phd-to-scientific-advisory-board 2021-03-08T08:39:44-05:00 https://ir.skyebioscience.com/news-releases/detail/106/skye-bioscience-to-present-at-h-c-wainwright-global-life-sciences-conference 2021-03-03T08:37:35-05:00 https://ir.skyebioscience.com/news-releases/detail/105/skye-bioscience-to-participate-in-investment-conferences-in-february 2021-02-03T09:09:38-05:00 https://ir.skyebioscience.com/news-releases/detail/104/emerald-bioscience-launches-rebrand-including-name-change-to-skye-bioscience 2021-01-19T08:30:01-05:00 https://ir.skyebioscience.com/news-releases/detail/103/emerald-bioscience-to-change-name-and-trading-symbol-effective-tuesday-january-19th 2021-01-15T13:30:00-05:00 https://ir.skyebioscience.com/news-releases/detail/102/emerald-bioscience-to-present-at-the-kcsa-cannabis-investor-conference 2021-01-05T08:30:03-05:00 https://ir.skyebioscience.com/news-releases/detail/101/emerald-bioscience-reports-that-superior-reduction-of-intraocular-pressure-of-its-unique-nanoemulsion-formulation-of-thcvhs-is-published-in-peer-reviewed-journal 2020-12-16T08:30:01-05:00 https://ir.skyebioscience.com/news-releases/detail/100/emerald-bioscience-to-present-at-the-benzinga-global-small-cap-virtual-conference 2020-12-07T08:45:02-05:00 https://ir.skyebioscience.com/news-releases/detail/99/emerald-bioscience-provides-corporate-update 2020-09-30T08:30:06-04:00 https://ir.skyebioscience.com/news-releases/detail/98/emerald-bioscience-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference 2020-09-03T11:39:04-04:00 https://ir.skyebioscience.com/news-releases/detail/97/emerald-bioscience-appoints-biotech-veteran-dr-margaret-dalesandro-to-board-of-directors 2020-08-13T08:30:10-04:00 https://ir.skyebioscience.com/news-releases/detail/96/emerald-bioscience-appoints-biotech-executive-punit-dhillon-as-ceo 2020-08-10T08:30:09-04:00 https://ir.skyebioscience.com/news-releases/detail/95/emerald-bioscience-raises-approximately-7-0-million-in-upsized-registered-offering 2020-08-04T18:32:17-04:00 https://ir.skyebioscience.com/news-releases/detail/94/emerald-bioscience-announces-pricing-of-7-0-million-upsized-registered-offering 2020-07-31T09:20:03-04:00 https://ir.skyebioscience.com/news-releases/detail/93/emerald-bioscience-announces-presentation-of-cannabidiol-valine-hemisuccinate-ocular-data-at-virtual-arvo-meeting 2020-06-09T09:37:21-04:00 https://ir.skyebioscience.com/news-releases/detail/92/emerald-bioscience-announces-awarding-of-patent-for-cannabidiol-valine-hemisuccinate-in-japan 2020-06-02T08:30:04-04:00 https://ir.skyebioscience.com/news-releases/detail/91/emerald-bioscience-joins-alliance-for-biosecurity 2020-04-08T08:30:10-04:00 https://ir.skyebioscience.com/news-releases/detail/90/emerald-bioscience-announces-notice-of-allowance-from-united-states-patent-office-for-proprietary-analog-of-cannabidiol 2020-03-09T08:30:10-04:00 https://ir.skyebioscience.com/news-releases/detail/89/emerald-bioscience-to-present-at-the-9th-annual-glaucoma-360-new-horizons-forum-and-bio-ceo-investor-forum 2020-01-30T08:30:05-05:00 https://ir.skyebioscience.com/news-releases/detail/88/emerald-bioscience-provides-update-on-recent-progress-and-expected-2020-milestones 2020-01-13T08:30:11-05:00 https://ir.skyebioscience.com/news-releases/detail/87/emerald-bioscience-to-present-at-biotech-showcase-2020 2020-01-09T08:30:09-05:00 https://ir.skyebioscience.com/news-releases/detail/25/emerald-bioscience-announces-financing-update-and-board-re-organization 2019-12-23T08:30:06-05:00 https://ir.skyebioscience.com/news-releases/detail/24/emerald-bioscience-inc-announces-cannabidiol-valine-hemisuccinate-possesses-enhanced-anti-seizure-activity-when-compared-with-cannabidiol-cbd-in-the-stemonix-human-neural-tissue-platform 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/23/emerald-bioscience-reports-its-proprietary-analog-of-cannabidiol-cannabidiol-valine-hemisuccinate-cbdvhs-exhibits-greater-potency-and-antifibrotic-activity-than-cannabidiol-cbd-in-biomarker-studies-in-human-ocular-donor-tissues 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/22/emerald-bioscience-announces-2-0-million-registered-direct-offering 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/21/emerald-bioscience-to-present-at-cowen-2nd-annual-boston-cannabis-conference 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/20/emerald-bioscience-to-present-research-data-related-to-its-glaucoma-drug-candidate-nb1111-at-2019-american-association-of-pharmaceutical-scientists 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/19/emerald-biosciences-nb1111-demonstrates-superiority-in-lowering-intraocular-pressure-compared-to-global-standard-of-care-glaucoma-treatment-in-preclinical-model 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/18/glauconix-presents-data-validating-impact-of-emerald-biosciences-prodrug-on-the-ocular-endocannabinoid-system-in-glaucoma 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/17/glauconix-biosciences-and-university-of-mississippi-to-present-research-data-related-to-emerald-biosciences-glaucoma-drug-candidate-nb1111-at-2019-american-academy-of-ophthalmology-annual-meeting 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/16/emerald-bioscience-to-participate-in-investment-and-scientific-conferences-in-september 2019-12-11T18:36:59-05:00 https://ir.skyebioscience.com/news-releases/detail/15/emerald-bioscience-appoints-chief-medical-officer-and-executive-director-clinical-operations 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/14/emerald-bioscience-starts-australian-operation-ahead-of-planned-glaucoma-study 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/13/emerald-bioscience-to-participate-in-29th-annual-international-cannabinoid-research-symposium-icrs 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/12/emerald-biosciences-nb2222-exhibits-superior-ocular-permeation-into-multiple-compartments-of-the-eye-compared-to-cannabidiol 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/11/emerald-bioscience-to-present-at-the-9th-annual-ld-micro-invitational 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/10/emerald-bioscience-secures-all-fields-licenses-for-cannabinoid-derivatives-developed-by-university-of-mississippi 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/9/emerald-bioscience-to-participate-at-the-cannastocks-2019-q1-investor-conference 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/8/emerald-bioscience-announces-ophthalmology-scientific-advisory-board-members 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/7/emerald-bioscience-to-present-at-the-2019-h-c-wainwright-global-life-sciences-conference 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/6/emerald-bioscience-inc-announces-dea-decision-that-its-proprietary-cannabidiol-analog-is-not-a-regulated-chemical-or-controlled-substance-under-controlled-substances-act 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/5/nemus-bioscience-inc-changes-name-to-emerald-bioscience-inc-and-provides-update-of-recent-research-accomplishments 2019-12-11T18:36:58-05:00 https://ir.skyebioscience.com/news-releases/detail/86/nemus-bioscience-reports-nanoemulsion-of-nb1111-superior-to-first-line-therapy-latanoprost-in-lowering-intraocular-pressure-in-validated-normotensive-animal-model-testing 2020-01-08T18:39:20-05:00 https://ir.skyebioscience.com/news-releases/detail/85/nemus-bioscience-to-present-at-31st-annual-roth-conference 2020-01-08T18:39:18-05:00 https://ir.skyebioscience.com/news-releases/detail/84/nemus-bioscience-confirms-nb1111-mechanism-of-action-and-reports-positive-results-from-glaucoma-biomarker-studies-in-human-donor-tissues 2020-01-08T18:39:18-05:00 https://ir.skyebioscience.com/news-releases/detail/83/nemus-bioscience-signs-agreement-with-noramco-to-manufacture-proprietary-cannabidiol-analog 2020-01-08T18:39:18-05:00 https://ir.skyebioscience.com/news-releases/detail/82/nemus-bioscience-signs-agreement-with-pharmaceuticals-international-inc-to-develop-dosage-formulation-for-human-dosing-with-nb1111-for-glaucoma 2020-01-08T18:39:17-05:00 https://ir.skyebioscience.com/news-releases/detail/81/nemus-bioscience-to-present-at-bio-ceo-investor-conference 2020-01-08T18:39:17-05:00 https://ir.skyebioscience.com/news-releases/detail/80/nemus-bioscience-to-present-at-the-noblecon-xv-and-8th-annual-glaucoma-360-new-horizons-forum 2020-01-08T18:39:16-05:00 https://ir.skyebioscience.com/news-releases/detail/79/nemus-bioscience-to-present-at-the-2nd-annual-sachs-neuroscience-innovation-forum-and-biotech-showcase-2019 2020-01-08T18:39:16-05:00 https://ir.skyebioscience.com/news-releases/detail/78/nemus-bioscience-to-present-at-investment-and-scientific-conferences-in-december 2020-01-08T18:39:16-05:00 https://ir.skyebioscience.com/news-releases/detail/77/nemus-bioscience-to-present-at-bio-investor-forum 2020-01-08T18:39:15-05:00 https://ir.skyebioscience.com/news-releases/detail/76/nemus-bioscience-announces-that-emerald-health-sciences-has-provided-a-credit-facility-of-up-to-20-million-and-adopted-an-open-market-share-purchase-program-of-up-to-10-million-common-shares 2020-01-08T18:39:14-05:00 https://ir.skyebioscience.com/news-releases/detail/75/nemus-bioscience-to-present-at-the-microcap-conference 2020-01-08T18:39:14-05:00 https://ir.skyebioscience.com/news-releases/detail/74/nemus-bioscience-to-present-at-the-rodman-renshaw-20th-annual-global-investment-conference 2020-01-08T18:39:14-05:00 https://ir.skyebioscience.com/news-releases/detail/73/update-nemus-bioscience-inc-signs-agreement-with-albany-molecular-research-inc-amri-to-manufacture-cannabinoid-based-active-pharmaceutical-ingredient-for-glaucoma 2020-01-08T18:39:13-05:00 https://ir.skyebioscience.com/news-releases/detail/72/nemus-bioscience-inc-signs-agreement-with-albany-molecular-research-inc-amri-to-manufacture-cannabinoid-based-active-pharmaceutical-ingredient-for-glaucoma 2020-01-08T18:39:13-05:00 https://ir.skyebioscience.com/news-releases/detail/71/nemus-bioscience-to-participate-at-the-8th-annual-ld-micro-invitational 2020-01-08T18:39:12-05:00 https://ir.skyebioscience.com/news-releases/detail/70/nemus-bioscience-adds-to-senior-leadership-team 2020-01-08T18:39:12-05:00 https://ir.skyebioscience.com/news-releases/detail/69/prominent-salk-institute-neuroscientist-joins-nemus-bioscience-as-scientific-consultant 2020-01-08T18:39:12-05:00 https://ir.skyebioscience.com/news-releases/detail/68/nemus-bioscience-to-participate-in-sachs-biocapital-usa-forum-at-the-new-york-academy-of-sciences 2020-01-08T18:39:11-05:00 https://ir.skyebioscience.com/news-releases/detail/67/emerald-health-strategic-majority-investor-in-nemus-bioscience-completes-final-closing-of-private-placement-investment-ahead-of-schedule 2020-01-08T18:39:11-05:00 https://ir.skyebioscience.com/news-releases/detail/66/nemus-bioscience-to-participate-in-bio-ceo-investor-conference-to-provide-ophthalmology-focused-pipeline-review 2020-01-08T18:39:11-05:00 https://ir.skyebioscience.com/news-releases/detail/65/nemus-secures-emerald-health-as-strategic-majority-investor-to-help-advance-clinical-development-of-novel-cannabinoid-based-therapeutics 2020-01-08T18:39:10-05:00 https://ir.skyebioscience.com/news-releases/detail/64/nemus-bioscience-announces-closing-of-convertible-bridge-loan-and-anticipated-equity-financing 2020-01-08T18:39:10-05:00 https://ir.skyebioscience.com/news-releases/detail/63/nemus-bioscience-files-arbitration-petition-against-schneider-finance-llc-and-sb-securities-ltd-for-failure-to-close-20-million-financing-and-failure-to-honor-guarantee 2020-01-08T18:39:09-05:00 https://ir.skyebioscience.com/news-releases/detail/62/nemus-bioscience-announces-presentation-of-cbd-analogue-therapeutic-data-related-to-neuropathic-pain-nb2111-and-ocular-diseases-nb2222-at-upcoming-scientific-meetings 2020-01-08T18:39:09-05:00 https://ir.skyebioscience.com/news-releases/detail/61/nemus-bioscience-announces-2000000-series-f-preferred-stock-financing 2020-01-08T18:39:08-05:00 https://ir.skyebioscience.com/news-releases/detail/60/nemus-bioscience-provides-further-update-on-previously-announced-20-million-schneider-financing 2020-01-08T18:39:07-05:00 https://ir.skyebioscience.com/news-releases/detail/59/nemus-bioscience-announces-presentation-of-cbd-analogue-nb2222-ocular-data-at-the-aaps-2017-annual-meeting 2020-01-08T18:39:07-05:00 https://ir.skyebioscience.com/news-releases/detail/58/nemus-bioscience-announces-presentation-of-nb2111-analgesic-and-anti-addiction-data-at-nih-sponsored-cannabinoid-conference 2020-01-08T18:39:06-05:00 https://ir.skyebioscience.com/news-releases/detail/57/nemus-bioscience-announces-nb2222-pain-and-anti-addiction-data-accepted-for-presentation-at-upcoming-society-of-neuroscience-meeting 2020-01-08T18:39:06-05:00 https://ir.skyebioscience.com/news-releases/detail/56/nemus-bioscience-provides-update-on-previously-announced-20-million-schneider-financing 2020-01-08T18:39:05-05:00 https://ir.skyebioscience.com/news-releases/detail/55/nemus-bioscience-announces-nb1111-data-presentation-at-the-27th-annual-symposium-of-the-international-cannabinoid-research-society-icrs 2020-01-08T18:39:04-05:00 https://ir.skyebioscience.com/news-releases/detail/54/nemus-bioscience-reports-prodrug-of-tetrahydrocannabinol-thc-issued-patent-coverage-in-canada-and-hong-kong 2020-01-08T18:39:04-05:00 https://ir.skyebioscience.com/news-releases/detail/53/nemus-bioscience-reports-prodrug-of-tetrahydrocannabinol-thc-receives-second-patent-issued-in-the-united-states-related-to-proprietary-delivery-mechanisms-for-treatment-of-glaucoma 2020-01-08T18:39:03-05:00 https://ir.skyebioscience.com/news-releases/detail/52/nemus-bioscience-announces-20-million-series-e-preferred-stock-financing 2020-01-08T18:39:02-05:00 https://ir.skyebioscience.com/news-releases/detail/51/nemus-bioscience-and-the-university-of-mississippi-announce-significant-anti-mrsa-synergy-data-utilizing-proprietary-cannabinoid-based-anti-infective-platforms 2020-01-08T18:39:01-05:00 https://ir.skyebioscience.com/news-releases/detail/50/nemus-bioscience-signs-development-agreement-with-nanomerics-to-advance-ocular-formulation-of-nb1111-for-the-treatment-of-glaucoma-using-proprietary-molecular-envelope-technology-met 2020-01-08T18:39:01-05:00 https://ir.skyebioscience.com/news-releases/detail/49/nemus-bioscience-and-catalent-to-advance-nb1222-into-human-dosage-formulation-development 2020-01-08T18:39:00-05:00 https://ir.skyebioscience.com/news-releases/detail/48/nemus-bioscience-inc-to-attend-upcoming-investment-conferences 2020-01-08T18:38:59-05:00 https://ir.skyebioscience.com/news-releases/detail/47/nemus-bioscience-announces-enhanced-ocular-tissue-concentration-by-the-proprietary-prodrug-of-tetrahydrocannabinol-nb1111---associated-with-a-superior-decline-in-intra-ocular-pressure-iop-in-an-animal-model 2020-01-08T18:38:58-05:00 https://ir.skyebioscience.com/news-releases/detail/46/nemus-bioscience-inc-announces-letter-of-intent-to-license-biosynthetic-technology-to-manufacture-its-proprietary-cannabinoid-molecules-from-teewinot-life-sciences-corp 2020-01-08T18:38:58-05:00 https://ir.skyebioscience.com/news-releases/detail/45/nemus-bioscience-identifies-unique-cannabidiol-cbd-derivative-as-a-lead-candidate-in-its-neuropathy-related-pain-management-program 2020-01-08T18:38:57-05:00 https://ir.skyebioscience.com/news-releases/detail/44/nemus-bioscience-ceo-to-present-at-the-28th-annual-roth-conference 2020-01-08T18:38:57-05:00 https://ir.skyebioscience.com/news-releases/detail/43/nemus-bioscience-inc-signs-agreement-with-albany-molecular-research-inc-amri-to-manufacture-cannabinoid-based-active-pharmaceutical-ingredients 2020-01-08T18:38:56-05:00 https://ir.skyebioscience.com/news-releases/detail/42/nemus-bioscience-ceo-to-present-at-bio-ceo-investor-conference 2020-01-08T18:38:55-05:00 https://ir.skyebioscience.com/news-releases/detail/41/nemus-enters-into-research-agreement-with-the-university-of-mississippi-to-develop-cannabinoid-based-therapies-for-chemotherapy-induced-peripheral-neuropathy-cipn 2020-01-08T18:38:55-05:00 https://ir.skyebioscience.com/news-releases/detail/40/nemus-announces-in-licensing-of-cannabidiol-cbd-derivatives-from-the-university-of-mississippi 2020-01-08T18:38:54-05:00 https://ir.skyebioscience.com/news-releases/detail/39/nemus-thc-pro-drug-receives-patent-in-japan 2020-01-08T18:38:53-05:00 https://ir.skyebioscience.com/news-releases/detail/38/nemus-bioscience-partners-with-atheln-to-accelerate-drug-development-pipelines 2020-01-08T18:38:53-05:00 https://ir.skyebioscience.com/news-releases/detail/37/nemus-bioscience-inc-to-attend-upcoming-investment-conferences 2020-01-08T18:38:52-05:00 https://ir.skyebioscience.com/news-releases/detail/36/distinguished-physician-scientist-dr-robert-n-weinreb-to-chair-the-nemus-ophthalmology-advisory-board 2020-01-08T18:38:51-05:00 https://ir.skyebioscience.com/news-releases/detail/35/nemus-bioscience-advances-lead-candidate-through-formulation-testing-prior-to-ind-enabling-studies 2020-01-08T18:38:51-05:00 https://ir.skyebioscience.com/news-releases/detail/34/nemus-bioscience-appoints-dr-brian-murphy-as-ceo 2020-01-08T18:38:50-05:00 https://ir.skyebioscience.com/news-releases/detail/33/nemus-bioscience-announces-closing-of-5-0-million-series-b-financing 2020-01-08T18:38:50-05:00 https://ir.skyebioscience.com/news-releases/detail/32/nemus-bioscience-announces-5-million-series-b-financing 2020-01-08T18:38:49-05:00 https://ir.skyebioscience.com/news-releases/detail/31/nemus-announces-research-agreement-with-the-university-of-mississippi-to-develop-proprietary-cannabidiol-cbd-molecules 2020-01-08T18:38:49-05:00 https://ir.skyebioscience.com/news-releases/detail/30/nemus-bioscience-announces-appointment-of-douglas-s-ingram-former-president-of-allergan-to-its-board-of-directors 2020-01-08T18:38:48-05:00 https://ir.skyebioscience.com/news-releases/detail/29/nemus-bioscience-inc-to-attend-upcoming-investment-conferences 2020-01-08T18:38:47-05:00 https://ir.skyebioscience.com/news-releases/detail/28/nemus-bioscience-announces-appointment-of-thomas-a-george-cfo-of-deckers-brands-to-its-board-of-directors 2020-01-08T18:38:47-05:00 https://ir.skyebioscience.com/news-releases/detail/27/nemus-to-move-forward-with-cannabinoid-based-therapy-for-open-angle-glaucoma 2020-01-08T18:38:47-05:00 https://ir.skyebioscience.com/news-releases/detail/26/nemus-bioscience-is-now-quoted-on-the-otc-bulletin-board-under-the-ticker-symbol-of-nmus 2020-01-08T18:38:46-05:00 https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20260310-2025-q4-financial-results-update-conference-call 2026-03-10T13:58:02-04:00 https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251204-piper-sandler-annual-healthcare-conference 2025-11-25T13:38:57-05:00 https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251203-evercore-annual-healthcare-conference 2025-11-24T18:39:58-05:00 https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251110-2025-q3-financial-results-update-conference-call 2025-11-07T18:21:13-05:00 https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251006-cbeyond-phase-2a-clinical-trial-topline-data-conference-call-webcast 2025-10-09T17:09:17-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023358/wk-form4_1775168549.html 2026-04-02T18:22:58-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023356/wk-form4_1775168465.html 2026-04-02T18:21:42-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023354/wk-form4_1775168412.html 2026-04-02T18:20:41-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023351/wk-form3a_1775168325.html 2026-04-02T18:19:09-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023349/wk-form4_1775168222.html 2026-04-02T18:17:37-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023346/wk-form4_1775168112.html 2026-04-02T18:15:40-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023343/wk-form4_1775167994.html 2026-04-02T18:14:10-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023340/wk-form4_1775167665.html 2026-04-02T18:11:01-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-023337/wk-form4_1775167579.html 2026-04-02T18:09:25-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-019878/skye-20260317.htm 2026-03-19T17:20:11-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-016585/skye-03102026_sx8evergreen.htm 2026-03-11T06:01:43-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-016400/skye-20260310.htm 2026-03-10T16:06:50-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-016394/skye-20251231.htm 2026-03-10T16:05:01-04:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-010186/skye_021826x8kkmaseparation.htm 2026-02-20T16:06:06-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006631/wk-form4_1770689187.html 2026-02-09T21:07:26-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006624/wk-form4_1770688482.html 2026-02-09T20:55:36-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006623/wk-form4_1770688476.html 2026-02-09T20:55:34-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006622/wk-form4_1770688470.html 2026-02-09T20:55:31-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006625/wk-form4_1770688487.html 2026-02-09T20:55:27-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006626/wk-form4_1770688493.html 2026-02-09T20:55:23-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006620/wk-form4_1770688461.html 2026-02-09T20:54:56-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006621/wk-form4_1770688465.html 2026-02-09T20:54:51-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006618/wk-form4_1770688448.html 2026-02-09T20:54:46-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-006619/wk-form4_1770688454.html 2026-02-09T20:54:40-05:00 https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001628280-26-004451/skye-20260202.htm 2026-02-02T07:06:12-05:00 https://ir.skyebioscience.com/privacy-policy https://ir.skyebioscience.com/disclaimer https://ir.skyebioscience.com/sitemap